A selective drug delivery system based on phospholipid-type nanobubbles for lung cancer therapy

Ming Hsien Chan, Yung Chieh Chan, Ru Shi Liu, Michael Hsiao*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

To develop a micelle-type nanobubble decorated with fluorescein-5-isothiocyanate-conjugated transferrin, with encapsulation of paclitaxel (PTX@FT-NB) for lung cancer treatment. Materials & methods: PTX@FT-NBs were characterized to determine their physicochemical properties, structural stability and cytotoxicity. Lung cancer cell and mouse xenograft tumor models were used to evaluate the therapeutic effectiveness of PTX@FT-NB. Results: The PTX@FT-NBs not only showed selective targeting to lung cancer cells but also inhibited tumor growth significantly via paclitaxel release. Furthermore, paclitaxel-induced microtubule stabilization demonstrated the release of the drug from PTX@FT-NB in the targeted tumor cell both in vitro and in vivo. Conclusion: PTX@FT-NB has the potential as an anticancer nanocarrier against lung cancer cells because of its specific targeting and better drug delivery capacity.

Original languageEnglish
Pages (from-to)2689-2705
Number of pages17
JournalNanomedicine
Volume15
Issue number27
DOIs
StatePublished - Nov 2020

Keywords

  • lung cancer cells
  • microtubule stabilization
  • nanobubble
  • paclitaxel
  • transferrin

Fingerprint

Dive into the research topics of 'A selective drug delivery system based on phospholipid-type nanobubbles for lung cancer therapy'. Together they form a unique fingerprint.

Cite this